.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Covington
Mallinckrodt
McKinsey
Novartis
Medtronic
QuintilesIMS
Deloitte
Dow
Johnson and Johnson

Generated: July 22, 2017

DrugPatentWatch Database Preview

Olanzapine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for olanzapine and what is the scope of olanzapine freedom to operate?

Olanzapine
is the generic ingredient in four branded drugs marketed by Teva Pharms, Ivax Pharms Inc, Aurobindo Pharma Ltd, Par Pharm, Ajanta Pharma Ltd, Torrent Pharms Llc, Qilu Pharm Co Ltd, Jubilant Generics, Dr Reddys Labs Ltd, Invagen Pharms, Torrent Pharms Ltd, Orchid Hlthcare, Sun Pharm Inds, Luitpold, Barr Labs Inc, Macleods Pharms Ltd, Lilly, Apotex Inc, Hikma Pharms Llc, Mylan Pharms Inc, Sandoz Inc, Alkem Labs Ltd, and Eli Lilly Co, and is included in thirty-five NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Olanzapine has twenty-six patent family members in twenty-three countries.

There are thirty-three drug master file entries for olanzapine. Forty-two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: olanzapine

Tradenames:4
Patents:3
Applicants:23
NDAs:35
Drug Master File Entries: see list33
Suppliers / Packagers: see list42
Bulk Api Vendors: see list92
Clinical Trials: see list391
Patent Applications: see list5,663
Therapeutic Class:Bipolar Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:olanzapine at DailyMed

Pharmacology for Ingredient: olanzapine

Tentative approvals for OLANZAPINE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe5MGTABLET; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc
OLANZAPINE
olanzapine
TABLET;ORAL076866-001Apr 23, 2012DISCNNoNo► Subscribe► Subscribe
Apotex Inc
OLANZAPINE
olanzapine
TABLET;ORAL090798-004Apr 23, 2012ABRXNoNo► Subscribe► Subscribe
Aurobindo Pharma Ltd
OLANZAPINE
olanzapine
TABLET, ORALLY DISINTEGRATING;ORAL203708-002May 15, 2014ABRXNoNo► Subscribe► Subscribe
Mylan Pharms Inc
OLANZAPINE
olanzapine
TABLET, ORALLY DISINTEGRATING;ORAL202285-001May 12, 2014ABRXNoNo► Subscribe► Subscribe
Dr Reddys Labs Ltd
OLANZAPINE
olanzapine
TABLET, ORALLY DISINTEGRATING;ORAL076534-001Oct 24, 2011ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: olanzapine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly
ZYPREXA ZYDIS
olanzapine
TABLET, ORALLY DISINTEGRATING;ORAL021086-004Apr 6, 20005,817,655► Subscribe
Lilly
ZYPREXA ZYDIS
olanzapine
TABLET, ORALLY DISINTEGRATING;ORAL021086-003Apr 6, 20005,817,656► Subscribe
Lilly
ZYPREXA ZYDIS
olanzapine
TABLET, ORALLY DISINTEGRATING;ORAL021086-002Apr 6, 20005,736,541► Subscribe
Lilly
ZYPREXA ZYDIS
olanzapine
TABLET, ORALLY DISINTEGRATING;ORAL021086-004Apr 6, 20005,229,382*PED► Subscribe
Lilly
ZYPREXA ZYDIS
olanzapine
TABLET, ORALLY DISINTEGRATING;ORAL021086-003Apr 6, 20005,229,382*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: olanzapine

Country Document Number Estimated Expiration
Turkey200003443► Subscribe
TaiwanI226829► Subscribe
Slovakia17512000► Subscribe
Eurasian Patent Organization004539► Subscribe
South Africa200006815► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: OLANZAPINE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0012Belgium► SubscribePRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927
C/GB96/058United Kingdom► SubscribePRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
70015Netherlands► SubscribePRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Novartis
Teva
Cantor Fitzgerald
Merck
Accenture
AstraZeneca
US Army
Express Scripts
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot